Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceGlobeNewsWire • 10/31/24
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/14/24
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 04/30/24
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”GlobeNewsWire • 04/09/24
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsGlobeNewsWire • 03/28/24
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024GlobeNewsWire • 02/29/24
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanGlobeNewsWire • 02/20/24
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingGlobeNewsWire • 02/08/24
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 02/08/24
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 02/06/24
Tenax Therapeutics shares soar after FDA clears IND for hypertension candidate NX-103Proactive Investors • 11/13/23
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023GlobeNewsWire • 11/13/23
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 07/19/23
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewsWire • 05/31/23